Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target

Gaetano Magro, Ivana Cataldo, Paolo Amico, Antonietta Torrisi, Giada Maria Vecchio, Rosalba Parenti, Sofia Asioli, Daniele Recupero, Velia D'Agata, Maria Teresa Mucignat, Roberto Perris

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background: Type I receptor for transferrin (TfR1/CD71) is overexpressed in several malignant tumors, but no studies are available on thyroid carcinomas. Our previous comparative analyses of the relative distribution of transferrin in benign versus papillary thyroid carcinoma (PTC) tissues highlighted a marked malignancy-associated abundance of the molecule. The aim of the present study was to evaluate whether TfR1/CD71 is also differentially expressed in benign versus malignant thyroid tissues. Methods: Tissue samples, including benign lesions and follicular-derived carcinomas, from 241 patients and a total of 35 benign and malignant fresh specimens were assayed for TfR1/CD71 expression by reverse transcriptase-polymerase chain reaction, Western blot, and immunohistochemistry. Results: We found that transcription of TfR1/CD71 gene is constitutive in thyroid epithelia, but the mRNA is differently translated in benign and malignant tissues. Western blot revealed higher levels of TfR1/CD71 protein in malignant versus benign tissues. Immunohistochemically, most carcinomas exhibited overexpression of the receptor, predominantly in the cytoplasm of neoplastic cells. The highest expression level was detected in primary and metastatic papillary carcinomas and anaplastic carcinomas, with positive results ranging from 86% to 100% of the cases. In contrast, most benign tissues were negative, with only a minority of cases showing focal and weak immunoreactivity. Conclusions: Our findings suggest that altered expression of TfR1/CD71 may be used as a marker helpful in distinguishing PTC from papillary hyperplasia and follicular variant PTC from benign follicular-patterned lesions. Additionally, the present observations support the rationale for the use of radiolabeled transferrin/transferrin analogs and/or anti-TfR1/CD71 antibodies for diagnostic and/or radiotherapeutic purposes in TfR1/CD71-expressing thyroid tumors.

Original languageEnglish
Pages (from-to)267-277
Number of pages11
JournalThyroid
Volume21
Issue number3
DOIs
Publication statusPublished - Mar 1 2011

Fingerprint

Thyroid Neoplasms
Transferrin
Thyroid Gland
Carcinoma
Therapeutics
Western Blotting
Carcinoma, Papillary, Follicular
Neoplasms
Transferrin Receptors
Papillary Carcinoma
Reverse Transcriptase Polymerase Chain Reaction
Hyperplasia
Cytoplasm
Epithelium
Immunohistochemistry
Messenger RNA
Antibodies
Genes
Papillary Thyroid cancer
Proteins

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Magro, G., Cataldo, I., Amico, P., Torrisi, A., Vecchio, G. M., Parenti, R., ... Perris, R. (2011). Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target. Thyroid, 21(3), 267-277. https://doi.org/10.1089/thy.2010.0173

Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target. / Magro, Gaetano; Cataldo, Ivana; Amico, Paolo; Torrisi, Antonietta; Vecchio, Giada Maria; Parenti, Rosalba; Asioli, Sofia; Recupero, Daniele; D'Agata, Velia; Mucignat, Maria Teresa; Perris, Roberto.

In: Thyroid, Vol. 21, No. 3, 01.03.2011, p. 267-277.

Research output: Contribution to journalArticle

Magro, G, Cataldo, I, Amico, P, Torrisi, A, Vecchio, GM, Parenti, R, Asioli, S, Recupero, D, D'Agata, V, Mucignat, MT & Perris, R 2011, 'Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target', Thyroid, vol. 21, no. 3, pp. 267-277. https://doi.org/10.1089/thy.2010.0173
Magro, Gaetano ; Cataldo, Ivana ; Amico, Paolo ; Torrisi, Antonietta ; Vecchio, Giada Maria ; Parenti, Rosalba ; Asioli, Sofia ; Recupero, Daniele ; D'Agata, Velia ; Mucignat, Maria Teresa ; Perris, Roberto. / Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target. In: Thyroid. 2011 ; Vol. 21, No. 3. pp. 267-277.
@article{06bca8a004dd474fbe4d70d4c552e7d2,
title = "Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target",
abstract = "Background: Type I receptor for transferrin (TfR1/CD71) is overexpressed in several malignant tumors, but no studies are available on thyroid carcinomas. Our previous comparative analyses of the relative distribution of transferrin in benign versus papillary thyroid carcinoma (PTC) tissues highlighted a marked malignancy-associated abundance of the molecule. The aim of the present study was to evaluate whether TfR1/CD71 is also differentially expressed in benign versus malignant thyroid tissues. Methods: Tissue samples, including benign lesions and follicular-derived carcinomas, from 241 patients and a total of 35 benign and malignant fresh specimens were assayed for TfR1/CD71 expression by reverse transcriptase-polymerase chain reaction, Western blot, and immunohistochemistry. Results: We found that transcription of TfR1/CD71 gene is constitutive in thyroid epithelia, but the mRNA is differently translated in benign and malignant tissues. Western blot revealed higher levels of TfR1/CD71 protein in malignant versus benign tissues. Immunohistochemically, most carcinomas exhibited overexpression of the receptor, predominantly in the cytoplasm of neoplastic cells. The highest expression level was detected in primary and metastatic papillary carcinomas and anaplastic carcinomas, with positive results ranging from 86{\%} to 100{\%} of the cases. In contrast, most benign tissues were negative, with only a minority of cases showing focal and weak immunoreactivity. Conclusions: Our findings suggest that altered expression of TfR1/CD71 may be used as a marker helpful in distinguishing PTC from papillary hyperplasia and follicular variant PTC from benign follicular-patterned lesions. Additionally, the present observations support the rationale for the use of radiolabeled transferrin/transferrin analogs and/or anti-TfR1/CD71 antibodies for diagnostic and/or radiotherapeutic purposes in TfR1/CD71-expressing thyroid tumors.",
author = "Gaetano Magro and Ivana Cataldo and Paolo Amico and Antonietta Torrisi and Vecchio, {Giada Maria} and Rosalba Parenti and Sofia Asioli and Daniele Recupero and Velia D'Agata and Mucignat, {Maria Teresa} and Roberto Perris",
year = "2011",
month = "3",
day = "1",
doi = "10.1089/thy.2010.0173",
language = "English",
volume = "21",
pages = "267--277",
journal = "Thyroid",
issn = "1050-7256",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target

AU - Magro, Gaetano

AU - Cataldo, Ivana

AU - Amico, Paolo

AU - Torrisi, Antonietta

AU - Vecchio, Giada Maria

AU - Parenti, Rosalba

AU - Asioli, Sofia

AU - Recupero, Daniele

AU - D'Agata, Velia

AU - Mucignat, Maria Teresa

AU - Perris, Roberto

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Background: Type I receptor for transferrin (TfR1/CD71) is overexpressed in several malignant tumors, but no studies are available on thyroid carcinomas. Our previous comparative analyses of the relative distribution of transferrin in benign versus papillary thyroid carcinoma (PTC) tissues highlighted a marked malignancy-associated abundance of the molecule. The aim of the present study was to evaluate whether TfR1/CD71 is also differentially expressed in benign versus malignant thyroid tissues. Methods: Tissue samples, including benign lesions and follicular-derived carcinomas, from 241 patients and a total of 35 benign and malignant fresh specimens were assayed for TfR1/CD71 expression by reverse transcriptase-polymerase chain reaction, Western blot, and immunohistochemistry. Results: We found that transcription of TfR1/CD71 gene is constitutive in thyroid epithelia, but the mRNA is differently translated in benign and malignant tissues. Western blot revealed higher levels of TfR1/CD71 protein in malignant versus benign tissues. Immunohistochemically, most carcinomas exhibited overexpression of the receptor, predominantly in the cytoplasm of neoplastic cells. The highest expression level was detected in primary and metastatic papillary carcinomas and anaplastic carcinomas, with positive results ranging from 86% to 100% of the cases. In contrast, most benign tissues were negative, with only a minority of cases showing focal and weak immunoreactivity. Conclusions: Our findings suggest that altered expression of TfR1/CD71 may be used as a marker helpful in distinguishing PTC from papillary hyperplasia and follicular variant PTC from benign follicular-patterned lesions. Additionally, the present observations support the rationale for the use of radiolabeled transferrin/transferrin analogs and/or anti-TfR1/CD71 antibodies for diagnostic and/or radiotherapeutic purposes in TfR1/CD71-expressing thyroid tumors.

AB - Background: Type I receptor for transferrin (TfR1/CD71) is overexpressed in several malignant tumors, but no studies are available on thyroid carcinomas. Our previous comparative analyses of the relative distribution of transferrin in benign versus papillary thyroid carcinoma (PTC) tissues highlighted a marked malignancy-associated abundance of the molecule. The aim of the present study was to evaluate whether TfR1/CD71 is also differentially expressed in benign versus malignant thyroid tissues. Methods: Tissue samples, including benign lesions and follicular-derived carcinomas, from 241 patients and a total of 35 benign and malignant fresh specimens were assayed for TfR1/CD71 expression by reverse transcriptase-polymerase chain reaction, Western blot, and immunohistochemistry. Results: We found that transcription of TfR1/CD71 gene is constitutive in thyroid epithelia, but the mRNA is differently translated in benign and malignant tissues. Western blot revealed higher levels of TfR1/CD71 protein in malignant versus benign tissues. Immunohistochemically, most carcinomas exhibited overexpression of the receptor, predominantly in the cytoplasm of neoplastic cells. The highest expression level was detected in primary and metastatic papillary carcinomas and anaplastic carcinomas, with positive results ranging from 86% to 100% of the cases. In contrast, most benign tissues were negative, with only a minority of cases showing focal and weak immunoreactivity. Conclusions: Our findings suggest that altered expression of TfR1/CD71 may be used as a marker helpful in distinguishing PTC from papillary hyperplasia and follicular variant PTC from benign follicular-patterned lesions. Additionally, the present observations support the rationale for the use of radiolabeled transferrin/transferrin analogs and/or anti-TfR1/CD71 antibodies for diagnostic and/or radiotherapeutic purposes in TfR1/CD71-expressing thyroid tumors.

UR - http://www.scopus.com/inward/record.url?scp=79952414715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952414715&partnerID=8YFLogxK

U2 - 10.1089/thy.2010.0173

DO - 10.1089/thy.2010.0173

M3 - Article

C2 - 21323588

AN - SCOPUS:79952414715

VL - 21

SP - 267

EP - 277

JO - Thyroid

JF - Thyroid

SN - 1050-7256

IS - 3

ER -